| Texto completo | |
| Autor(es): Mostrar menos - |
Matos, Aline de Moura Brasil
;
Gomes, Andre Borges Ferreira
;
Carvalho, Fernanda Martins Maia
;
de Oliveira, Francisco Tomaz Meneses
;
da Silva, Lohana Santana Almeida
;
Dahy, Flavia Esper
;
de Moura, Joao Victor Luisi
;
Freire, Marcela Vieira
;
Vidal, Jose Ernesto
;
Marcusso, Rosa Maria Nascimento
;
Smid, Jerusa
;
Procaci, Victor Rebelo
;
Massaud, Rodrigo Meireles
;
Von Glehn, Felipe
;
Casseb, Jorge
;
Romano, Camila Malta
;
de Oliveira, Augusto Cesar Penalva
;
NeurocovBR Study Grp, Mariana
Número total de Autores: 18
|
| Tipo de documento: | Artigo Científico |
| Fonte: | BMC INFECTIOUS DISEASES; v. 25, n. 1, p. 12-pg., 2025-01-27. |
| Resumo | |
Background Neurological manifestations associated with COVID-19 remain partially described, mainly in low- and middle-income countries where diagnostic tools are limited. To address this, we assembled medical centers in Brazil with the goal of describing neurological syndromes associated with COVID-19 during the first wave of the pandemic. Methods From June 1st, 2020 to June 1st, 2021, non-consecutive adult patients with new onset of six neurological syndromes up to 60 days after confirmed COVID-19 were included. Data were compiled from four tertiary centers and compared with general local COVID-19 data, as well as with a previous cohort focused on vascular syndrome. Results 197 patients were included, presenting with vascular syndromes (81), encephalopathy (68), encephalitis (19), Guillain-Barr & eacute; syndrome (13), other neuropathies (12), and myelitis (4). The incidence curve of neurocovid mirrored that of COVID-19. Neurological syndromes were present regardless of COVID-19 severity. The median time from COVID-19 to onset of neurological symptoms was 14 days, suggesting a post-infectious immune-mediated mechanism. Patients were 10 times more likely to die (chi 2 (1) = 356.55, p < 0.01, OR = 10.89) and 38 times more likely to be hospitalized than other COVID-19 patients (chi 2 (1) = 1167.9, p < 0.01, OR = 38.22). Those developing vascular syndromes patients were 3 times more likely to require ICU (chi 2 (1) = 37.12, p < 0.01, OR = 3.78) and 4 times more likely to die (chi 2 (1) = 58.808, p < 0.01, OR = 4.73) than patients with vascular syndromes due to different etiologies. Conclusions Our study corroborates the association of neurological syndromes with COVID-19. The incidence correlated with local waves of COVID-19, and patients with neurocovid exhibited a higher susceptibility to adverse outcomes compared to other COVID-19 patients. Among all neurological syndromes, vascular syndromes were the most common, and their severity surpassed that of vascular syndromes not attributed to COVID-19. (AU) | |
| Processo FAPESP: | 20/05984-2 - Manifestações neurológicas agudas associadas ao vírus SARS-CoV-2 |
| Beneficiário: | Jorge Simao do Rosario Casseb |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |